Work

Complement inhibition does not impair the clinical antiviral capabilities of virus-specific T-cell therapy

Year: 2020

Type: article

Abstract: Key Points The use of terminal complement blockade is compatible with virus-specific T-cell (VST) expansion and clinical effectiveness. VST and complement-blocking agent concurrent therapy may be safely used in patients with thrombotic microangiopathy and viral infections.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2020002252

Authors: Jeremy D. Rubinstein, Xiang Zhu, Carolyn Lutzko, Tom Leemhuis, Jose A. Cancelas, Sonata Jodele, Catherine M. Bollard, Patrick J. Hanley, Stella M. Davies, Michael S. Grimley, Adam S. Nelson

Institutions: University of Cincinnati, Cincinnati Children's Hospital Medical Center, Children's National, George Washington University

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funder: Eunice Kennedy Shriver National Institute of Child Health and Human Development

Award: Thrombotic microangiopathy (TMA) associated MODS after stem cell transplantation

OpenAlex ID: W3043962314

FWCI: 0.35

Cites: 25

Cited by: 6

Related to: 10